{"protocolSection": {"identificationModule": {"nctId": "NCT00634036", "orgStudyIdInfo": {"id": "GLITZ 001"}, "secondaryIdInfos": [{"id": "00001949"}], "organization": {"fullName": "University of Pittsburgh", "class": "OTHER"}, "briefTitle": "Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics", "officialTitle": "A Randomized, Placebo-Controlled Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics", "acronym": "GLITZ Asthma"}, "statusModule": {"statusVerifiedDate": "2017-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-10"}, "primaryCompletionDateStruct": {"date": "2012-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-03-05", "studyFirstSubmitQcDate": "2008-03-11", "studyFirstPostDateStruct": {"date": "2008-03-12", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-03-18", "resultsFirstSubmitQcDate": "2017-06-19", "resultsFirstPostDateStruct": {"date": "2017-07-19", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-06-19", "lastUpdatePostDateStruct": {"date": "2017-07-19", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR_INVESTIGATOR", "investigatorFullName": "Fernando Holguin", "investigatorTitle": "Principal Investigator", "investigatorAffiliation": "University of Pittsburgh"}, "leadSponsor": {"name": "Fernando Holguin", "class": "OTHER"}, "collaborators": [{"name": "Takeda", "class": "INDUSTRY"}, {"name": "University of Vermont", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "Asthmatics who are significantly overweight tend to have more severe symptoms, more flare ups, and are more likely to have poorly-controlled asthma when compared to other asthmatics.\n\nResearchers believe this occurs because excess adipose tissue (fat) in the body can cause higher-than-normal levels of leptin and lower-than-normal levels of adiponectin in the blood.\n\nThe researchers of this study are testing a medication called pioglitazone in overweight asthmatics because they believe it can help regulate leptin and adiponectin and that this may improve symptoms of asthma.", "detailedDescription": "Participants in this study will be randomly assigned (like the flip of a coin) to pioglitazone or a placebo (an inactive pill). They will be given study medication to take everyday for 12 weeks (3 months).\n\nParticipants will complete a number of asthma-related questionnaires and a variety of pulmonary function tests. Participants will undergo physical exams, an electrocardiogram, and blood sampling to measure leptin, adiponectin, markers of inflammation, blood cell counts, glucose levels, BNP hormone levels, and liver function.\n\nTo monitor participants throughout the study, follow-up visits will be done at 2, 6, and 12 weeks after starting study drug. At these visits many of the pulmonary function tests and questionnaires will be repeated."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "obesity", "exacerbation", "asthmatics", "fat", "overweight", "adipose tissue", "leptin", "adiponectin", "pioglitazone", "Actos", "wheezing", "Pittsburgh", "Pennsylvania", "pulmonary", "lung"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 23, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: pioglitazone"]}, {"label": "2", "type": "PLACEBO_COMPARATOR", "interventionNames": ["Drug: placebo"]}], "interventions": [{"type": "DRUG", "name": "pioglitazone", "description": "pioglitazone tablets: 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)", "armGroupLabels": ["1"], "otherNames": ["Actos"]}, {"type": "DRUG", "name": "placebo", "description": "matching placebo (inert tablet)", "armGroupLabels": ["2"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Airway Reactivity", "description": "Presence and degree of airway hyperresponsiveness assessed by methacholine challenge test. PC20= Methacholine dose at wich the FEV1 deops by \\> 20% from pre-methacholine baseline values.", "timeFrame": "12 weeks"}], "secondaryOutcomes": [{"measure": "FEV1 % Predicted", "timeFrame": "12 weeks"}, {"measure": "Juniper Asthma Control Questionnaire", "description": "The Juniper Asthma Control Questionnaire is a validated scale ranging from 0 to 6. Higher scores represent poorer asthma control. Values \\> 1.5 are compatible with poorly controlled asthma", "timeFrame": "12 weeks"}, {"measure": "Exhaled Nitric Oxide Ppb", "timeFrame": "12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Asthma diagnosed by a physician at least 1 year prior to study enrollment\n* Poorly-controlled asthma at study enrollment\n* Non smokers (stopped smoking at least 1 year ago) and limited life-time history of smoking\n* Body mass index 30-60\n* Responds to methacholine challenge test with PC20 of \\<16 mg/ml\n* On a stable dose of inhaled corticosteroid for at least 4 weeks prior to study entry\n* FEV1 \\>60% predicted\n* Able to obtain weekly weights at home\n\nExclusion Criteria:\n\n* Systemic steroids within the past 4 weeks\n* Lung pathology other than asthma\n* Other significant non-pulmonary co-morbidities such as: coronary artery disease, peripheral vascular disease, cerebrovascular disease, congestive heart failure with an ejection fraction \\<50%, liver disease or elevated liver enzymes at baseline, malignancy (excluding non-melanoma skin cancers), AIDS, renal failure with serum creatinine \\>3.0, or disorders requiring steroid treatment such as vasculitis, lupus, rheumatoid arthritis\n* B-type natriuretic peptide (BNP) \\>400 pg/mL\n* Pregnant or lactating\n* Currently taking a beta blocker, a CYP2C8 inhibitor or inducer such as gemfibrozil or rifampin, a TZD (thiazolidinedione), or allergic to TZD\n* Taking antioxidants or nutritional supplements (stable dose of calcium, vitamin D, or multivitamin is OK)\n* Illicit drug use within the past year\n* Current/active upper respiratory infection (if active URI, wait until asymptomatic for 1 week to enroll)\n* Asthma exacerbation within the past 4 weeks (includes ER, urgent care, or hospital visits due to asthma resulting in an increase in asthma-related medications)\n* Undergoing evaluation for sleep apnea, or plans to institute treatment for sleep apnea (patients on a stable treatment regimen for sleep apnea for the last 3 months will be allowed to participate)\n* Clinically significant abnormalities present on screening 12-lead electrocardiogram\n* Women of childbearing potential using oral contraceptives who are not willing to use a second method of contraception during the study", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "60 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Fernando Holguin, MD, MPH", "affiliation": "University of Pittsburgh", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Anne E. Dixon, MD", "affiliation": "University of Vermont", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Pittsburgh", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15213", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "University of Vermont", "city": "Colchester", "state": "Vermont", "zip": "05446", "country": "United States", "geoPoint": {"lat": 44.54394, "lon": -73.14791}}]}, "referencesModule": {"references": [{"pmid": "11815521", "type": "BACKGROUND", "citation": "Hashimoto Y, Nakahara K. Improvement of asthma after administration of pioglitazone. Diabetes Care. 2002 Feb;25(2):401. doi: 10.2337/diacare.25.2.401. No abstract available."}, {"pmid": "16815147", "type": "BACKGROUND", "citation": "Lee KS, Kim SR, Park SJ, Park HS, Min KH, Jin SM, Lee MK, Kim UH, Lee YC. Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice. J Allergy Clin Immunol. 2006 Jul;118(1):120-7. doi: 10.1016/j.jaci.2006.03.021. Epub 2006 May 19."}, {"pmid": "26610598", "type": "DERIVED", "citation": "Dixon AE, Subramanian M, DeSarno M, Black K, Lane L, Holguin F. A pilot randomized controlled trial of pioglitazone for the treatment of poorly controlled asthma in obesity. Respir Res. 2015 Nov 26;16:143. doi: 10.1186/s12931-015-0303-6."}], "seeAlsoLinks": [{"label": "Asthma informational website", "url": "http://www.nhlbi.nih.gov/health/dci/Diseases/Asthma/Asthma_WhatIs.html"}, {"label": "Asthma informational website", "url": "http://www.ginasthma.com/"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Pioglitazone", "description": "pioglitazone tablets: 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)"}, {"id": "FG001", "title": "Placebo", "description": "matching placebo (inert tablet)"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "11"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Pioglitazone", "description": "pioglitazone: pioglitazone tablets: 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)"}, {"id": "BG001", "title": "Placebo", "description": "placebo: matching placebo (inert tablet)"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "23"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "23"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "39.4", "spread": "10"}, {"groupId": "BG001", "value": "41", "spread": "14.1"}, {"groupId": "BG002", "value": "40.2", "spread": "12.05"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "15"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "8"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "6"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "17"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "23"}]}]}]}, {"title": "Age asthma onset", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "15", "spread": "11"}, {"groupId": "BG001", "value": "21", "spread": "18.9"}, {"groupId": "BG002", "value": "18", "spread": "14.95"}]}]}]}, {"title": "Body Mass Index", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "38.8", "spread": "6.8"}, {"groupId": "BG001", "value": "43.5", "spread": "7.8"}, {"groupId": "BG002", "value": "41.15", "spread": "7.3"}]}]}]}, {"title": "Seasonal allergies", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Reported allergies", "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "20"}]}]}, {"title": "Non-allergic", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}]}]}, {"title": "Gastroesophageal Reflux Disease (GERD)", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Participants with GERD", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "12"}]}]}, {"title": "Participants without GERD", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}]}]}, {"title": "Depression", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Participants reporting Depression", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "13"}]}]}, {"title": "Participants without Depression", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "10"}]}]}]}, {"title": "Asthma exacerbation in last 12 months", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Reported an exacerbation", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "13"}]}]}, {"title": "No reported exacerbation", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "10"}]}]}]}, {"title": "Oral steroids in last 12 months", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Used oral steroids", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "11"}]}]}, {"title": "Did not use oral steroids", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "12"}]}]}]}, {"title": "Inhaled corticosteroid", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "High dose", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "9"}]}]}, {"title": "Medium dose", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "12"}]}]}, {"title": "Low dose", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}]}]}]}, {"title": "Long acting beta agonist", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Used long acting beta agonist", "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "19"}]}]}, {"title": "Did not use long acting beta agonist", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "4"}]}]}]}, {"title": "Short acting beta agonist", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Used short acting beta agonist", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "22"}]}]}, {"title": "Did not use short acting beta agonist", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Exhaled Nitric Oxide", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ppb", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "27.6", "spread": "27.8"}, {"groupId": "BG001", "value": "30.8", "spread": "28.4"}, {"groupId": "BG002", "value": "29.2", "spread": "28.1"}]}]}]}, {"title": "Immunoglobulin E", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "IU/ml", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "291.2", "spread": "313.2"}, {"groupId": "BG001", "value": "575", "spread": "544.7"}, {"groupId": "BG002", "value": "433.1", "spread": "428.95"}]}]}]}, {"title": "Juniper Asthma Control", "description": "Scale Range: minimum 1.0; maximum 6.0 Higher values represent increased asthma symptoms A score greater than 1.5 is considered compatible with uncontrolled asthma", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "scores on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.75", "spread": ".63"}, {"groupId": "BG001", "value": "2.48", "spread": "1.3"}, {"groupId": "BG002", "value": "2.115", "spread": ".965"}]}]}]}, {"title": "FEV1 (% predicted before bronchodilator use)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "% predicted", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "82.3", "spread": "12.1"}, {"groupId": "BG001", "value": "81.5", "spread": "15.2"}, {"groupId": "BG002", "value": "81.9", "spread": "13.65"}]}]}]}, {"title": "FVC (% predicted before bronchodilator use)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "% predicted", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "86.8", "spread": "13.7"}, {"groupId": "BG001", "value": "85.3", "spread": "16.2"}, {"groupId": "BG002", "value": "86.05", "spread": "14.95"}]}]}]}, {"title": "FEV1/FVC (% predicted before bronchodilator use)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "% predicted", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "95.3", "spread": "11.2"}, {"groupId": "BG001", "value": "94.9", "spread": "11.12"}, {"groupId": "BG002", "value": "95.1", "spread": "11.16"}]}]}]}, {"title": "FEV1 (% predicted after bronchodilator use)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "% predicted", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "77.3", "spread": "25.1"}, {"groupId": "BG001", "value": "88.1", "spread": "4.6"}, {"groupId": "BG002", "value": "82.7", "spread": "14.85"}]}]}]}, {"title": "FVC (% predicted after bronchodilator use)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "% predicted", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "79.5", "spread": "27.6"}, {"groupId": "BG001", "value": "88.3", "spread": "16.3"}, {"groupId": "BG002", "value": "83.9", "spread": "21.95"}]}]}]}, {"title": "FEV1/FVC (% predicted after bronchodilator use)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "% predicted", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "90.9", "spread": "31.2"}, {"groupId": "BG001", "value": "97.8", "spread": "7.82"}, {"groupId": "BG002", "value": "94.35", "spread": "19.51"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Airway Reactivity", "description": "Presence and degree of airway hyperresponsiveness assessed by methacholine challenge test. PC20= Methacholine dose at wich the FEV1 deops by \\> 20% from pre-methacholine baseline values.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "mg/ml", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Pioglitazone", "description": "pioglitazone tablets: 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)"}, {"id": "OG001", "title": "Placebo", "description": "matching placebo (inert tablet)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.08", "lowerLimit": "0", "upperLimit": "7.42"}, {"groupId": "OG001", "value": "2.37", "lowerLimit": "0", "upperLimit": "11.22"}]}]}]}, {"type": "SECONDARY", "title": "FEV1 % Predicted", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "% predicted", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Pioglitazone", "description": "pioglitazone tablets: 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)"}, {"id": "OG001", "title": "Placebo", "description": "matching placebo (inert tablet)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "80.3", "spread": "15"}, {"groupId": "OG001", "value": "85.2", "spread": "12"}]}]}]}, {"type": "SECONDARY", "title": "Juniper Asthma Control Questionnaire", "description": "The Juniper Asthma Control Questionnaire is a validated scale ranging from 0 to 6. Higher scores represent poorer asthma control. Values \\> 1.5 are compatible with poorly controlled asthma", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Pioglitazone", "description": "pioglitazone tablets: 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)"}, {"id": "OG001", "title": "Placebo", "description": "matching placebo (inert tablet)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.62", "spread": ".6"}, {"groupId": "OG001", "value": "1.82", "spread": "1"}]}]}]}, {"type": "SECONDARY", "title": "Exhaled Nitric Oxide Ppb", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ppb", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Pioglitazone", "description": "pioglitazone tablets: 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)"}, {"id": "OG001", "title": "Placebo", "description": "matching placebo (inert tablet)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "27.6", "spread": "27.8"}, {"groupId": "OG001", "value": "30.8", "spread": "28.4"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Pioglitazone", "description": "pioglitazone tablets: 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)", "seriousNumAffected": 0, "seriousNumAtRisk": 12, "otherNumAffected": 12, "otherNumAtRisk": 12}, {"id": "EG001", "title": "Placebo", "description": "matching placebo (inert tablet)", "seriousNumAffected": 0, "seriousNumAtRisk": 11, "otherNumAffected": 11, "otherNumAtRisk": 11}], "otherEvents": [{"term": "Headache", "organSystem": "General disorders", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 11}]}, {"term": "Dizziness", "organSystem": "General disorders", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 11}]}, {"term": "Upper Respiratory Infection", "organSystem": "Respiratory, thoracic and mediastinal disorders", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 11}]}, {"term": "Sore Throat", "organSystem": "General disorders", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 11}]}, {"term": "Abdominal pain", "organSystem": "General disorders", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 11}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}]}, {"term": "Diarrhea", "organSystem": "Gastrointestinal disorders", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 11}]}, {"term": "Skin rash", "organSystem": "Skin and subcutaneous tissue disorders", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}]}, {"term": "Muscle aches", "organSystem": "General disorders", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 11}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Dr. Fernando Holguin", "organization": "University of Pittsburgh", "email": "holguinf@upmc.edu", "phone": "412-692-2817"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M26186", "name": "Overweight", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M12701", "name": "Obesity", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077205", "term": "Pioglitazone"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M1693", "name": "Pioglitazone", "asFound": "Registry", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}